This page requires you to enable JavaScript in your web browser for complete functionality.
Healthwise

Retinopathy, Arteriosclerotic


National Organization for Rare Disorders, Inc.

Synonyms

  • Arteriosclerosis, Retina

Disorder Subdivisions

  • None

Related Disorders List

Information on the following diseases can be found in the Related Disorders section of this report:

  • Hypertensive Retinopathy
  • Papilledema (Choked Disk)

General Discussion

Arteriosclerotic Retinopathy is a series of changes in the retina that are caused by arteriosclerosis. It is characterized by bleeding in the retina, thick fluid oozing from the retina, impaired oxygenation of the retina, an abrupt reduction of blood flow to the heart muscle that may cause dying off of tissue (myocardial infarction), and hardening of the walls of the little arteries (arterioles) in the eye. These degenerative changes can cause vision impairment.
.

Symptoms

In Arteriosclerotic Retinopathy the opening (lumen) of the little arteries (arterioles) in the retina is irregular. The retina is the layer of the eyeball that contains the light sensitive nerve cells. This layer also contains a large number of little blood vessels. This disorder causes thickening of the arterial walls which in turn causes the arterioles to become contorted.

Flame shaped or pinpoint spots of bleeding may also occur, although they are apparent only during examination of the eye with an ophthalmoscope. The retina may show oozing of thick liquid, and dying tissue (necrosis) in certain spots. The place where the optic nerve enters the retina (optic disk or papilla) as seen by the ophthalmologist, may be blurred. The retina may become detached, and arterial spasm may occur. Eventually internal bleeding or clotting (thrombosis) of the central vein and withering away (atrophy) of the retina may result, which can cause progressive vision impairment.

Causes

Arteriosclerotic Retinopathy usually occurs as a result of progressive hardening of the blood vessels by calcification and loss of elastic tissue (arteriosclerosis). Arteriosclerosis is a general term which includes a number of blood vessel diseases such as fatty degeneration of the arteries (atherosclerosis), and may also include changes in the shape of the arteries. With age, the blood vessels often become more contorted and less elastic. Certain biochemical, physical and environmental factors, known as risk factors may predispose an individual to arteriosclerosis.

Affected Populations

Arteriosclerotic Retinopathy affects persons with fatty degeneration (atherosclerosis), and hardening of the arteries (arteriosclerosis). This type of Retinopathy usually affects people over age 50 years

Related Disorders

Hypertensive Retinopathy is a syndrome of changes in the retina caused by hypertension. It is characterized by progressive changes in the little arteries (arterioles) of the eye and swelling (edema), resulting in vision impairment. (For more information, choose "hypertensive retinopathy" as your search term in the Rare Disease Database.)

Papilledema (Choked Disk) is a swelling (edema) of the portion of the retina where the optic nerve enters the eyeball. The swelling is due to increased pressure inside the skull that may be caused by a variety of conditions.

Standard Therapies

Therapy for Arteriosclerotic Retinopathy consists of treating the underlying arteriosclerosis. An excess of lipids in the blood (hyperlipidemia) can be prevented by changes in dietary habits. Fat intake should be reduced, and saturated fats should be replaced with polyunsaturated fats. The intake of cholesterol, saturated and short-chain fatty acids (such as those in meats or dairy products), should be reduced. Weight reduction to normal, or even slightly under current statistical norms, is recommended. Drugs may be required in certain patients to reduce blood cholesterol and lipids.

Prevention of arteriosclerosis is possible by good control of diabetes when present, and by weight loss if obesity is a factor. Cigarette smoking may also aggravate arteriosclerosis and should be limited or stopped. Regular exercise may be a helpful therapeutic measure. Hypertension should be identified and treated early.

Investigational Therapies

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222
TTY: (866) 411-1010
Email: prpl@cc.nih.gov

For information about clinical trials sponsored by private sources, contact:
www.centerwatch.com

References

TEXTBOOKS
Bennett JC, Plum F., eds. Cecil Textbook of Medicine. 20th ed. Philadelphia, PA: W.B. Saunders Co; 1996:2181.

Beers MH, Berkow R., eds. The Merck Manual, 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:729.

REVIEW ARTICLE
Bhagat N, et al., Central retinal vein occlusion: review of management. Eur J Ophthalmol. 1999;9:165-80.

JOURNAL ARTICLES
Schimkat M, et al., [Mitral valve prolapse. A possible cause of retinal vascular occlusion in young patients]. Ophthalmologe. 1993;90:476-78. German.

Tomikawa S, et al., [Lipoprotein (a) and sclerotic changes in retinal arterioles]. Nippon Ganka Gakkai Zasshi. 1993;97:967-74. Japanese.

Rabb MF, et al., Retinal arterial macroaneurysms. Surv Ophthalmol. 1988;33:73-96.

Trushko IA., [Possibilities of the color stress test in the early diagnosis and evaluation of the effectiveness of treatment of arteriosclerotic retinal dystrophies]. Oftalmol Zh. 1986;4:229-231.

Resources

National Association for Visually Handicapped
22 West 21st Street
New York, NY 10010
USA
Tel: (212)889-3141
Fax: (212)727-2931
Email: staff@navh.org
Internet: http://www.navh.org

Schepens Eye Research Institute
20 Staniford Street
Boston, MA 02114-2500
Tel: (617)912-0100
Fax: (617)912-0101
Email: geninfo@vision.eri.harvard.edu
Internet: http://www.theschepens.org/

American Council of the Blind, Inc.
1155 15th Street
Suite 1004
Washington, DC 20005
Tel: (202)467-5081
Fax: (202)467-5085
Tel: (800)424-8666
Internet: http://www.acb.org

American Foundation for the Blind
11 Penn Plaza
Suite 300
New York, NY 10001
Tel: (212)502-7600
Fax: (212)502-7777
Tel: (800)232-5463
TDD: (212)502-7662
Email: afbinfo@afb.org
Internet: http://www.afb.org

Council of Families with Visual Impairment
1155 15th St. NW
Suite 1004
Washington, DC 20005
Tel: (202)465-5081
Fax: (202)465-5085
Email: info@acb.org
Internet: http://www.acb.org/

American Heart Association
National Center
7272 Greenville Avenue
Dallas, TX 75231-4596
Tel: (214)373-6300
Fax: (214)373-0268
Tel: (800)242-8721
Email: inquire@heart.org
Internet: http://www.americanheart.org

National Eye Research Foundation
910 Skokie Boulevard
Suite 207A
Northbrook, IL 60062
Tel: (847)564-4652
Fax: (847)564-0807
Tel: (800)621-2258
Email: nerf1955@aol.com
Internet: http://www.nerf.org

NIH/National Eye Institute
Building 31 Rm 6A32
31 Center Dr MSC 2510
Bethesda, MD 20892-2510
United States
Tel: (301)496-5248
Fax: (301)402-1065
Email: 2020@nei.nih.gov
Internet: http://www.nei.nih.gov/

For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). CIGNA members can access the complete report by logging into myCIGNA.com. For non-CIGNA members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.

The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only. NORD recommends that affected individuals seek the advice or counsel of their own personal physicians.

It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report

This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.

For additional information and assistance about rare disorders, please contact the National Organization for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site www.rarediseases.org or email orphan@rarediseases.org

Last Updated:  4/14/2008
Copyright  1987, 1989, 2000 National Organization for Rare Disorders, Inc.



This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.